Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 1/20 | 0.48 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19695909 | 0.85 | LTB4R (0.52) | LTB4RCYP3A4CYP2C9CYP2C19NPC1 | |
| SCHEMBL19695907 | 0.85 | LTB4R (0.52) | LTB4RCYP3A4CYP2C9CYP2C19NPC1 | |
| SCHEMBL2950480 | 0.84 | LTB4R (0.61) | LTB4RCYP3A4CYP2C9CYP2C19NPC1 | |
| SCHEMBL2947337 | 0.83 | LTB4R (0.48) | LTB4RDEGS1HCAR2RBP4NPC1 | |
| SCHEMBL19695945 | 0.80 | LTB4R (0.56) | LTB4RDEGS1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6790194 | 0.78 | HCAR2 (0.63) | LTB4RDEGS1HCAR2ROCK2 | |
| SCHEMBL6790198 | 0.78 | HCAR2 (0.63) | LTB4RDEGS1HCAR2ROCK2 | |
| SCHEMBL6790187 | 0.78 | HCAR2 (0.63) | LTB4RDEGS1HCAR2ROCK2 | |
| SCHEMBL15396459 | 0.78 | LTB4R (0.47) | LTB4RDEGS1HCAR2ROCK2NPC1 | |
| SCHEMBL13002056 | 0.77 | LTB4R (0.55) | LTB4RCYP3A4CYP2C9CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583535-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2023-02-21 | — | — | US | disclosed |
| US-20210244741-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-10786510-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2020-09-29 | — | — | US | disclosed |
| EP-3485883-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OccuRx Pty Ltd (AU) | 2019-05-22 | — | — | EP | disclosed |
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | OCCURX PTY LTD (AU) | 2018-05-03 | — | — | US | disclosed |
| US-9839640-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | OCCURX PTY LTD (AU) | 2017-12-12 | — | — | US | disclosed |
| WO-2012068612-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2012-05-31 | — | — | WO | disclosed |
| WO-2010144959-A1 | ANALOGUES OF ANTI-FIBROTIC AGENTS | FIBROTECH THERAPEUTICS PTY LTD (AU) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117049-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | LTB4R 77/4885DEGS1 3945/4885HCAR2 199/4885 |
| US-20210244741-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | LTB4R 77/4885DEGS1 3945/4885HCAR2 199/4885 |
| US-20180117050-A1 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION | VCAM1, PTGIS, NFKBIA | LTB4R 77/4885DEGS1 3945/4885HCAR2 199/4885 |
| US-11583535-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | LTB4R 77/4885DEGS1 3945/4885HCAR2 199/4885 |
| US-10786510-B2 | Methods of treating eye diseases associated with inflammation and vascular proliferation | VCAM1, PTGIS, NFKBIA | LTB4R 77/4885DEGS1 3945/4885HCAR2 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.